Cipla’s subsidiary InvaGen Pharmaceuticals Inc has received nod from the US health regulator for Sevelamer Carbonate tablets, which are suggested for the control of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.
Cipla in a BSE filing stated that, “its subsidiary, InvaGen Pharmaceuticals Inc. has received final approval for its abbreviated new drug application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA).”
Further, the company will start the commercial launch of the product immediately.
